Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.40 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.40 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.40 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.40 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.40 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.40 |
| ▸ | GRIN3A | Q8TCU5 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.36 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.36 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.36 |
| ▸ | FLT1 | P17948 | 1/20 | 0.36 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12869693 | 0.84 | SMN1; SMN2 (0.49) | SMN1; SMN2PKMGRIN2DGRIN3BGRIN1 | |
| SCHEMBL18641437 | 0.84 | SOS1 (0.44) | SMN1; SMN2SOS1PKMGRIN2DGRIN3B | |
| SCHEMBL31056505 | 0.80 | SMN1; SMN2 (0.50) | SMN1; SMN2PKMGRIN2DGRIN3BGRIN1 | |
| SCHEMBL27816651 | 0.80 | SMN1; SMN2 (0.50) | SMN1; SMN2PKMGRIN2DGRIN3BGRIN1 | |
| SCHEMBL26927384 | 0.79 | GRIN2D (0.51) | SMN1; SMN2PKMGRIN2DGRIN3BGRIN1 | |
| SCHEMBL28418045 | 0.79 | SOS1 (0.44) | SMN1; SMN2SOS1PKMKDM4EALDH1A1 | |
| SCHEMBL12566398 | 0.78 | SMN1; SMN2 (0.48) | SMN1; SMN2PKMGRIN2DGRIN3BGRIN1 | |
| SCHEMBL3298748 | 0.77 | KDM4E (0.50) | SOS1PKMKDM4EALDH1A1HPGD | |
| SCHEMBL12869691 | 0.76 | SMN1; SMN2 (0.41) | SMN1; SMN2PKMGRIN2DGRIN3BGRIN1 | |
| SCHEMBL28878161 | 0.76 | SMN1; SMN2 (0.41) | SMN1; SMN2PKMGRIN2DGRIN3BGRIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7737166-B2 | Antifungal bicyclic hetero ring compounds | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2010-06-15 | — | — | US | disclosed |
| US-20090143353-A1 | such as 2-tert-Butyl-7-[(3S)-3-(dimethylamino)pyrrolidin-1-yl]-5-methyl-6-phenyl-1,3-benzoxazole-4-carbonitrile hydrochloride, a 1,6-beta-glucan synthetase inhibitor having potent growth inhibition, used treating a fungal infections; fungicides | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-06-04 | — | — | US | disclosed |
| EP-1932837-A1 | BICYCLO HETEROCYCLIC COMPOUND HAVING ANTIFUNGAL ACTION | Daiichi Sankyo Company, Limited (JP) | 2008-06-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143353-A1 | such as 2-tert-Butyl-7-[(3S)-3-(dimethylamino)pyrrolidin-1-yl]-5-methyl-6-phenyl-1,3-benzoxazole-4-carbonitrile hydrochloride, a 1,6-beta-glucan synthetase inhibitor having potent growth inhibition, used treating a fungal infections; fungicides | CTPS1, TPP1, STS | SMN1; SMN2 3267/4885SOS1 2013/4885PKM 1135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.